API
< Back to all clusters
[BUSINESS] · United Kingdom, United States, India · 2 sources

started · updated

USFDA issues four observations following inspection of Zydus LiqMeds facility in UK

The US Food and Drug Administration (USFDA) has concluded an inspection of the LiqMeds facility in the United Kingdom, operated by Zydus Lifesciences, with four observations. The inspection took place from November 9 to November 13, 2026.

LiqMeds, which was acquired by Ahmedabad-based Zydus Lifesciences in October 2023, specializes in the development, manufacturing, and supply of oral liquid pharmaceutical products. The facility located in Weedon, Northampton, supplies products to both the UK and US markets.

Zydus Lifesciences stated in a regulatory filing that the company intends to work closely with the USFDA to address the observations expeditiously.

Entities

LiqMeds · US Food and Drug Administration · United Kingdom · United States · Zydus Lifesciences